Pfizer (PFE) Operating Income (2009 - 2026)
Pfizer (PFE) posted quarterly Operating Income of $5.4 billion for Q1 2026, up 7.74% year-over-year from $5.0 billion in Q1 2025, and up 111.09% quarter-over-quarter from -$48.7 billion in Q4 2025.
Pfizer (PFE) Operating Income (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Operating Income for 18 consecutive years, with $5.4 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 7.74% year-over-year to $5.4 billion; the TTM figure through Mar 2026 stood at -$44.2 billion (down 282.12% YoY), while the FY2025 annual figure was -$32.1 billion, up 14.18% from the prior year.
- Operating Income advanced to $5.4 billion in Q1 2026 per PFE's latest filing, from -$48.7 billion in the prior quarter.
- Across five years, Operating Income topped out at $14.0 billion in Q3 2024 and bottomed at -$48.7 billion in Q4 2025.
- Historically, Operating Income has averaged -$1.8 billion across 5 years, with a median of $5.0 billion in 2025.
- Annual changes were most pronounced in 2024 — Operating Income jumped 175.79% — and 2025, when it sank 3979.56%.
- Pfizer's Operating Income stood at $13.0 billion in 2022, then sank by 208.0% to -$14.1 billion in 2023, then jumped by 199.47% to $14.0 billion in 2024, then tumbled by 447.64% to -$48.7 billion in 2025, then soared by 111.09% to $5.4 billion in 2026.
- Business Quant data shows PFE's Operating Income at $5.4 billion in Q1 2026, -$48.7 billion in Q4 2025, and $6.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 4.27 Bn |
| Mar 29, 2026 | 5.40 Bn |
| Dec 31, 2025 | -48.70 Bn |
| Sep 28, 2025 | 6.51 Bn |
| Jun 29, 2025 | -7.38 Bn |
| Mar 30, 2025 | 5.02 Bn |
| Sep 29, 2024 | 14.01 Bn |
| Jun 30, 2024 | -181.00 Mn |
| Mar 31, 2024 | 5.41 Bn |
| Dec 31, 2023 | -14.09 Bn |
| Jul 2, 2023 | -6.03 Bn |
| Apr 2, 2023 | -7.14 Bn |
| Jul 3, 2022 | 13.04 Bn |
| Apr 3, 2022 | 10.59 Bn |
| Oct 3, 2021 | 20.20 Bn |
| Jul 4, 2021 | 6.74 Bn |
| Apr 4, 2021 | 5.57 Bn |
| Sep 27, 2020 | 10.17 Bn |
| Jun 28, 2020 | 2.96 Bn |
| Mar 29, 2020 | 3.88 Bn |